FY2024 EPS Estimate for Stereotaxis Decreased by Analyst

Stereotaxis, Inc. (NYSEAMERICAN:STXS) – Roth Capital reduced their FY2024 earnings estimates for Stereotaxis in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.24) per share for the year, down from their previous forecast of ($0.22). The consensus estimate for Stereotaxis’ current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Stereotaxis’ Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.

Stereotaxis Stock Performance

STXS opened at $2.09 on Friday. Stereotaxis has a 12 month low of $1.41 and a 12 month high of $3.29.

Stereotaxis (NYSEAMERICAN:STXS) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 153.10%.

Hedge Funds Weigh In On Stereotaxis

Several hedge funds have recently modified their holdings of STXS. SG Americas Securities LLC bought a new position in shares of Stereotaxis during the 3rd quarter valued at about $39,000. Forum Financial Management LP bought a new stake in Stereotaxis during the second quarter worth approximately $48,000. Virtu Financial LLC grew its position in Stereotaxis by 56.0% in the first quarter. Virtu Financial LLC now owns 32,690 shares of the company’s stock worth $85,000 after buying an additional 11,739 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Stereotaxis by 645.6% in the second quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after buying an additional 41,780 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Stereotaxis by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 167,297 shares of the company’s stock valued at $341,000 after acquiring an additional 15,491 shares during the last quarter. 45.35% of the stock is currently owned by institutional investors and hedge funds.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.